Risk factors for recurrent disease after resection of solitary fibrous tumor: a systematic review.

pathology prognosis risk factor sarcoma solitary fibrous tumor

Journal

Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127

Informations de publication

Date de publication:
2024
Historique:
received: 02 11 2023
accepted: 05 01 2024
medline: 15 2 2024
pubmed: 15 2 2024
entrez: 15 2 2024
Statut: epublish

Résumé

Solitary fibrous tumor (SFT) is a rare soft tissue tumor found at any site of the body. The treatment of choice is surgical resection, though 10%-30% of patients experience recurrent disease. Multiple risk factors and risk stratification systems have been investigated to predict which patients are at risk of recurrence. The main goal of this systematic review is to create an up-to-date systematic overview of risk factors and risk stratification systems predicting recurrence for patients with surgically resected SFT within torso and extremities. We prepared the review following the updated Prisma guidelines for systematic reviews (PRISMA-P). Pubmed, Embase, Cochrane Library, WHO international trial registry platform and ClinicalTrials.gov were systematically searched up to December 2022. All English studies describing risk factors for recurrence after resected SFT were included. We excluded SFT in the central nervous system and the oto-rhino-laryngology region. Eighty-one retrospective studies were identified. Different risk factors including age, symptoms, sex, resection margins, anatomic location, mitotic index, pleomorphism, hypercellularity, necrosis, size, dedifferentiation, CD-34 expression, Ki67 index and Mitotic index, necrosis and Ki67 index are the most solid risk factors for recurrence. TERT promoter mutation seems a promising component in future risk stratification models. The Demicco risk stratification system is the most validated and widely used, however the G-score model may appear to be superior due to longer follow-up time. CRD42023421358.

Identifiants

pubmed: 38357190
doi: 10.3389/fsurg.2024.1332421
pmc: PMC10864472
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1332421

Informations de copyright

© 2024 Tolstrup, Loya, Aggerholm-Pedersen, Preisler and Penninga.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Johan Tolstrup (J)

Department of Surgery and Transplantation, Rigshospitalet, Copenhagen, Denmark.

Anand Loya (A)

Department of Pathology, Rigshospitalet, Copenhagen, Denmark.

Ninna Aggerholm-Pedersen (N)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Louise Preisler (L)

Department of Surgery and Transplantation, Rigshospitalet, Copenhagen, Denmark.

Luit Penninga (L)

Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.

Classifications MeSH